Emergent BioSolutions Inc.
HealthcareNYSE:EBS · New York Stock Exchange
-$0.07 today
Vol 0.40M · Avg 0.75M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $52.6M +127.6% | -$190.6M +74.9% | -$760.5M -259.4% | -$211.6M -191.6% | $230.9M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $95.8M -11.9% | $108.8M -13.0% | $125.1M -12.7% | $143.3M +15.8% | $123.8M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | -$4.0M +27.3% | -$5.5M +38.2% | -$8.9M +68.9% | -$28.6M -161.0% | $46.9M | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $16.2M -10.0% | $18.0M -22.1% | $23.1M -48.8% | $45.1M +6.4% | $42.4M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$22.4M -125.3% | $88.7M +226.2% | -$70.3M -3247.6% | -$2.1M +98.7% | -$156.4M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $25.5M +204.5% | -$24.4M -13.0% | -$21.6M -118.3% | $118.1M +345.0% | -$48.2M | $592.6M | $1.3B | $626.2M |
| Inventory | -$30.3M -23.7% | -$24.5M -4183.3% | $600.0K +101.1% | -$57.1M -29.8% | -$44.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$8.4M +74.5% | -$33.0M -411.3% | $10.6M +175.7% | -$14.0M -460.0% | -$2.5M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$9.2M -105.4% | $170.6M +384.8% | -$59.9M -22.0% | -$49.1M +20.4% | -$61.7M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $32.4M -17.6% | $39.3M -91.9% | $485.2M +2350.5% | $19.8M -40.9% | $33.5M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | $170.6M +190.6% | $58.7M +128.5% | -$206.3M -505.0% | -$34.1M -110.6% | $321.1M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$13.8M +39.7% | -$22.9M +55.6% | -$51.6M +55.4% | -$115.8M +48.5% | -$225.0M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 -100.0% | $270.2M | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $0 | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | $83.2M -43.8% | $148.1M +2450.8% | -$6.3M +97.6% | -$265.5M | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $69.4M -44.6% | $125.2M -41.0% | $212.3M +155.7% | -$381.3M -69.5% | -$225.0M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$112.5M +43.3% | -$198.4M +63.5% | -$543.4M -196.3% | $564.2M +1671.6% | -$35.9M | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $2.2M -76.3% | $9.3M +10.7% | $8.4M | $0 | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$24.9M | $0 | $0 +100.0% | -$82.1M +22.5% | -$106.0M | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | -$1.4M -55.6% | -$900.0K -28.6% | -$700.0K +22.2% | -$900.0K -200.0% | $900.0K | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$136.6M +28.1% | -$190.0M +64.5% | -$535.7M -211.3% | $481.2M +441.3% | -$141.0M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $100.0K | $0 +100.0% | -$1.2M -340.0% | $500.0K +266.7% | -$300.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $103.5M +1796.7% | -$6.1M +98.9% | -$530.9M -900.8% | $66.3M +246.7% | -$45.2M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | $156.8M +338.0% | $35.8M +113.9% | -$257.9M -72.0% | -$149.9M -256.0% | $96.1M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
COMPASS Pathways plc
NASDAQ:CMPS
$1.16B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
Esperion Therapeutics, Inc.
NASDAQ:ESPR
$654.91M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$607.79M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
Aquestive Therapeutics, Inc.
NASDAQ:AQST
$414.11M
SNDL Inc.
NASDAQ:SNDL
$369.44M
SIGA Technologies, Inc.
NASDAQ:SIGA
$309.85M
Organogenesis Holdings Inc.
NASDAQ:ORGO
$301.10M
SEC Filings
Recent regulatory filings
No filings found.
Does EBS generate free cash flow?
Emergent BioSolutions Inc. (EBS) generated $156.80M of free cash flow in fiscal 2025.
How much operating cash flow does EBS produce?
Operating cash flow was $170.60M, before capital expenditures of $13.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.